Drug intelligence / Profile preview

IHP-101

Development stage: Preclinical
Lead developer: IHP Therapeutics
Modality: Small Molecules

Overview

IHP-101 is a preclinical-stage small molecule therapeutic being developed by IHP Therapeutics. It is designed to target both the complement system and P-selectin, with the primary goal of treating solid tumors that overexpress sialyl Lewis (sLe) antigens. By inhibiting these pathways, IHP-101 aims to disrupt tumor-promoting inflammatory processes and potentially interfere with tumor cell adhesion and metastasis.

Targets

SELP (P-selectin)Complement (Complement system)

Beyond the preview

Go deeper on IHP-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IHP-101.

Explore the full profile